Enterprise Value

14.87B

Cash

858.4M

Avg Qtr Burn

N/A

Short % of Float

0.14%

Insider Ownership

0.41%

Institutional Own.

14.91%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ORPATHYS (Savolitinib) (C-MET inhibitor) Details
Non-small cell lung carcinoma, Cancer, Colorectal cancer , Renal cell carcinoma, Gastric cancer

Approved

Quarterly sales

ELUNATE (Fruquintinib) (VEGFR 1/2/3) Details
Colorectal cancer , Metastatic colorectal cancer, Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Quarterly sales

ELUNATE (Fruquintinib) + paclitaxel Details
Solid tumor/s, Cancer, Gastroesophageal adenocarcinomas, Gastric cancer

NDA

Acceptance for review

NDA

Submission

ORPATHYS (Savolitinib) (C-MET inhibitor) Details
Renal cell carcinoma, Cancer, Gastric cancer

Phase 3

Data readout

ORPATHYS (Savolitinib) + TAGRISSO Details
Non-small cell lung carcinoma, Cancer

Phase 3

Interim Update

SULANDA (Surufatinib) Details
Solid tumor/s, Pancreatic cancer, Neuroendocrine tumor, Cholangiocarcinoma, Cancer

Phase 3

Update

Tazemetostat Details
Follicular lymphoma

Phase 2

Data readout

Phase 2

Data readout

HMPL-453 (FGFR 1/2/3) Details
Mesothelioma, Intrahepatic cholangiocarcinoma , Cancer

Phase 2

Update

ELUNATE (Fruquintinib) + Sintilimab Details
Solid tumor/s, Cancer, Triple-negative breast cancer , Endometrial cancer, Renal cell carcinoma

Phase 1/2

Data readout

Sovleplenib (HMPL-523) (Syk inhibitor) Details
Warm autoimmune hemolytic anemia

Phase 1/2

Update

Phase 1/2

Initiation

HMPL-306 Details
Blood cancer, Hematologic malignancies

Failed

Discontinued